High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

被引:0
|
作者
M. C. Walter
H. Lochmüller
M. Toepfer
B. Schlotter
P. Reilich
M. Schröder
W. Müller-Felber
D. Pongratz
机构
[1] Department of Neurology,
[2] Friedrich-Baur-Institut,undefined
[3] Medizinische Klink,undefined
[4] University of Munich,undefined
[5] Ziemssenstrasse 1a,undefined
[6] D-80336 Munich,undefined
[7] Germany e-mail: Maggie.Walter@lrz.uni-muenchen.de,undefined
[8] Tel.: +49-89-51603933,undefined
[9] Fax: +49-89-51602203,undefined
来源
Journal of Neurology | 2000年 / 247卷
关键词
Key words Sporadic inclusion body myositis; Inflammatory myopathy; Immunoglobulin therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Sporadic inclusion body myositis (s-IBM) is an acquired inflammatory muscle disease of unknown cause. In general, s-IBM presents with slowly progressive, asymmetric weakness, and atrophy of skeletal muscle. There is a mild transitory or nil responsiveness to standard immunosuppressive treatment. A controlled cross-over study of ¶22 s-IBM patients over 3 months showed a partial improvement in those treated with high-dose intravenous immunoglobulin therapy (IVIG) versus placebo. The present study included 22 patients aged 32–75 years and with a mean duration of disease of 5.2 ± 3.6 years. They were randomized by a double-blind, placebo-controlled, cross-over design to monthly infusions of ¶2 g/kg bodyweight IVIG or to placebo for 6 months each, followed by the alternative treatment. After 6 and 12 months the response to treatment was evaluated, using a modified Medical Research Council scale, Neuromuscular Symptom Score (NSS), the patient’s own assessment of improvement, arm outstretched time, and electromyography. No serious side effects were seen, in particular no viral infection and no major cardiac or neurological complications. Overall there was no progression of the disease in 90% of patients, unlike that which might have been expected in untreated patients. A mild and significant improvement (11%) in clinical symptoms was found using NSS, but not with other test procedures. There was a trend to mild improvement in treated patients when using other tests. Individual responses to treatment was heterogeneous. The validity of this study may be reduced by mismatch of groups with regard to age at onset and variability in disease expression. The findings of this study largely confirm those of a previous IVIG trial. Treatment with IVIG may be mildly effective in s-IBM by preventing disease progression or inducing mild improvement. Long-term studies are needed to evaluate further the benefit of IVIG therapy in s-IBM.
引用
收藏
页码:22 / 28
页数:6
相关论文
共 50 条
  • [1] High-dose immunoglobulin therapy in sporadic inclusion body myositis:: a double-blind, placebo-controlled study
    Walter, MC
    Lochmüller, H
    Toepfer, M
    Schlotter, B
    Reilich, P
    Schröder, M
    Müller-Felber, W
    Pongratz, D
    JOURNAL OF NEUROLOGY, 2000, 247 (01) : 22 - 28
  • [2] High dose intravenous immunoglobulin (IVIG) in the treatment of inclusion body myositis:: A double-blind, placebo-controlled study
    Hirschmann, M
    Lochmüller, H
    Toepfer, M
    Schlotter, B
    Schröder, M
    Müller-Felber, W
    Naumann, M
    Schneider, C
    Toyka, KV
    Pongratz, DE
    NEUROLOGY, 1998, 50 (04) : A368 - A369
  • [3] A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
    Amato, Anthony A.
    Badrising, Umesh
    Benveniste, Olivier
    Needham, Merrilee
    Chinoy, Hector
    Wu, Min
    Koumaras, Barbara
    de Vera, Ana
    Papanicolaou, Dimitris A.
    Hanna, Michael G.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] RESILIENT: A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients With Sporadic Inclusion Body Myositis
    Amato, Anthony A.
    Badrising, Umesh
    Benveniste, Olivier
    Needham, Merrilee
    Chinoy, Hector
    Wu, Min
    Koumaras, Barbara
    de Vera, Ana
    Papanicolaou, Dimitris A.
    Hanna, Michael G.
    NEUROLOGY, 2017, 88
  • [5] A double-blind, placebo-controlled trial of oxandrolone in inclusion body myositis
    Rutkove, SB
    Parker, RA
    Nardin, RA
    Connolly, CE
    Felice, KJ
    Raynor, EM
    NEUROLOGY, 2001, 56 (08) : A464 - A464
  • [6] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ARIMOCLOMOL IN PATIENTS WITH INCLUSION BODY MYOSITIS
    Machado, Pedro M.
    Barohn, Richard J.
    McDermott, Michael
    Blaettler, Thomas
    Lloyd, Thomas
    Shaibani, Aziz
    Freimer, Miriam
    Amato, Anthony
    Ciafaloni, Emma
    Jones, Sarah
    Mozaffar, Tahseen
    Gibson, Summer
    Wicklund, Matthew
    Levine, Todd
    Sundgreen, Claus
    Carstensen, Tim Dehli
    Bonefeld, Karen K.
    Jorgensen, Anders N.
    Phonekeo, Karina
    Heim, Andrew J.
    Herbelin, Laura
    Hanna, Michael G.
    Dimachkie, Mazen M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 417 - 417
  • [7] Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
    Dalakas, MC
    Sonies, B
    Dambrosia, J
    Sekul, E
    Cupler, E
    Sivakumar, K
    NEUROLOGY, 1997, 48 (03) : 712 - 716
  • [8] A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
    Machado, Pedro
    Barohn, Richard
    McDermott, Michael
    Blaetter, Thomas
    Lloyd, Tom
    Shaibani, Aziz
    Freimer, Miriam
    Amato, Anthony
    Ciafaloni, Emma
    Jones, Sarah
    Mozaffar, Tahseen
    Gibson, Summer
    Wicklund, Matthew
    Levine, Todd
    Sundgreen, Claus
    Carstensen, Tim
    Bonefeld, Karen
    Jorgensen, Anders
    Phonekeo, Karina
    Heim, Andrew
    Herbelin, Laura
    Hanna, Michael
    Dimachkie, Mazen
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 907 - 908
  • [9] A Randomized, Double-Blind, Placebo-Controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
    Machado, Pedro M.
    Barohn, Richard J.
    McDermott, Michael
    Blaetter, Thomas
    Lloyd, Tom
    Shaibani, Aziz
    Freimer, Miriam
    Amato, Anthony A.
    Ciafaloni, Emma
    Jones, Sarah M.
    Mozaffar, Tahseen
    Gibson, Summer
    Wicklund, Matthew
    Levine, Todd
    Sundgreen, Claus
    Carstensen, Tim
    Bonefeld, Karen K.
    Jorgensen, Anders N.
    Phonekeo, Karina
    Heim, Andrew
    Herbelin, Laura
    Hanna, Michael
    Dimachkie, Mazen M.
    ANNALS OF NEUROLOGY, 2021, 90 : S223 - S224
  • [10] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN THE TREATMENT OF DERMATOMYOSITIS (DM) - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    DALAKAS, MC
    MCCROSKY, S
    DAMBROSIA, JM
    ILLA, I
    SOUEIDAN, SA
    OTERO, C
    STEIN, DP
    DINSMORE, ST
    SONIES, BC
    NEUROLOGY, 1993, 43 (04) : A356 - A357